跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
李 伯璋
講座教授
,
公共衛生學院
電子郵件
094038
tmu.edu
tw
h-index
929
引文
15
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1993 …
2023
每年研究成果
概覽
指紋
網路
研究成果
(50)
類似的個人檔案
(6)
指紋
查看啟用 Po-Chang Lee 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Kidney Graft
100%
Nephrectomy
49%
Cyclosporine
42%
Allograft
36%
Kidney Transplantation
34%
Effective Kidney Plasma Flow
31%
Bezoar
31%
Everolimus
31%
Liver Dysfunction
31%
Transplantation
29%
Surgical Technique
27%
Glomerular Filtration Rate
27%
Immunosuppressive Treatment
26%
Ingestion
25%
Renal Artery
21%
Calcineurin Inhibitor
19%
Mycophenolic Acid
19%
Bowel Obstruction
18%
Overall Survival
17%
Kidney Function
16%
Randomized Controlled Trial
15%
Immune Checkpoint Inhibitor
15%
Met-Enkephalin
15%
Cholestasis
15%
Epidermal Growth Factor Receptor
15%
Fifth Disease
15%
Cohort Analysis
15%
Non Small Cell Lung Cancer
15%
Peliosis Hepatis
15%
Reticulin
15%
Alternariosis
15%
Incentive
15%
Antinociception
15%
Ascites
15%
Contraindication
15%
Morphine
15%
Interim Analysis
15%
Diabetes Mellitus
15%
Peroperative Complication
15%
Acute Graft Rejection
13%
Surgery
12%
Jejunum Ulcer
12%
Stomach Surgery
12%
Diverticulum
12%
Biopsy
11%
Bovine Serum Albumin
11%
Creatinine
10%
Targeted Therapy
9%
Artery Reconstruction
9%
Hepatitis Virus
7%
Immunology and Microbiology
Transplant Procedure
76%
Kidney Transplantation
73%
Human Leukocyte Antigen
67%
Immune Complex
49%
HLA Antibody
47%
Allotransplantation
45%
Chronic Graft Rejection
35%
Monospecific Antibody
34%
Enzyme-Linked Immunosorbent Assay
21%
Alloantibody
18%
Immunosuppressive Drug
17%
Mycophenolic Acid
17%
Effective Kidney Plasma Flow
15%
Immunosuppression
15%
Everolimus
15%
Titer
15%
Ciclosporin
15%
ELISA
9%
Glomerulus Filtration
9%
Epitope
7%
Plasmapheresis
5%
Immunosuppressive Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ciclosporin
58%
Mycophenolic Acid
47%
Randomized Controlled Trial
31%
Tacrolimus
31%
Bezoar
31%
Intestine Obstruction
18%
Overall Survival
17%
Metenkephalin
15%
Erythema Infectiosum
15%
Everolimus
15%
Cohort Study
15%
Non Small Cell Lung Cancer
15%
Antinociception
15%
Liver Dysfunction
15%
Rapamycin
15%
Epidermal Growth Factor Receptor
15%
Morphine
15%
Postmarketing Surveillance
15%
Cholestasis
15%
Diabetes Mellitus
15%
Alternariosis
15%
Diverticulosis
12%
Jejunum Ulcer
12%
Immunosuppressive Agent
10%
Chemotherapy
9%
Alternaria
7%
Infection
6%
Obstruction
6%
Recurrent Disease
6%
Ulcer
6%
Hepatitis C Virus
6%
Adverse Event
5%
Graft Failure
5%
Malignant Neoplasm
5%
Acute Graft Rejection
5%
